Jason Gerberry
Stock Analyst at B of A Securities
(3.67)
# 918
Out of 4,608 analysts
146
Total ratings
55.34%
Success rate
4.27%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Maintains: Buy | $52 → $62 | $48.57 | +27.65% | 1 | Sep 24, 2024 | |
| RLAY Relay Therapeutics | Maintains: Buy | $20 → $24 | $6.55 | +266.41% | 1 | Sep 10, 2024 | |
| PROK ProKidney | Maintains: Neutral | $4 → $3 | $1.71 | +75.95% | 3 | Sep 4, 2024 | |
| PCVX Vaxcyte | Maintains: Buy | $101 → $140 | $115.54 | +21.17% | 3 | Sep 4, 2024 | |
| BLUE bluebird bio | Maintains: Buy | $4 → $3 | $0.47 | +537.35% | 7 | Aug 15, 2024 | |
| AXSM Axsome Therapeutics | Upgrades: Buy | $95 → $106 | $90.51 | +17.11% | 4 | Aug 6, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $67 → $68 | $39.07 | +74.05% | 5 | Jul 23, 2024 | |
| OCS Oculis Holding AG | Maintains: Buy | $21 → $20 | $12.09 | +65.43% | 3 | Jun 11, 2024 | |
| TEVA Teva Pharmaceutical | Maintains: Buy | $18 → $21 | $17.67 | +18.85% | 12 | May 30, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | $82 → $91 | $72.65 | +25.26% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $28.50 | +8.77% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $0.26 | +4,147.10% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $20.22 | +13.75% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $28.83 | +0.59% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $37 | $19.18 | +92.91% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $40.38 | +38.68% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $39.24 | -23.55% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $51 | $28.45 | +79.26% | 3 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $63 | $48.35 | +30.30% | 1 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $11.49 | -21.67% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $204 → $217 | $109.04 | +99.01% | 5 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $4 → $2 | $0.39 | +410.20% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $884.48 | -43.47% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $6 → $4 | $0.29 | +1,293.73% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $50 | $81.44 | -38.61% | 3 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $2.67 | +237.08% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $18.83 | +32.77% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $2.41 | +107.47% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $8.27 | +226.48% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $1.02 | +1,860.78% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $10 | $1.37 | +629.93% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $196.96 | -51.77% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $52.90 | +13.42% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $37 | $28.67 | +29.05% | 4 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $114.74 | -21.56% | 11 | Oct 17, 2019 |
Biohaven
Sep 24, 2024
Maintains: Buy
Price Target: $52 → $62
Current: $48.57
Upside: +27.65%
Relay Therapeutics
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $6.55
Upside: +266.41%
ProKidney
Sep 4, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $1.71
Upside: +75.95%
Vaxcyte
Sep 4, 2024
Maintains: Buy
Price Target: $101 → $140
Current: $115.54
Upside: +21.17%
bluebird bio
Aug 15, 2024
Maintains: Buy
Price Target: $4 → $3
Current: $0.47
Upside: +537.35%
Axsome Therapeutics
Aug 6, 2024
Upgrades: Buy
Price Target: $95 → $106
Current: $90.51
Upside: +17.11%
Ionis Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $67 → $68
Current: $39.07
Upside: +74.05%
Oculis Holding AG
Jun 11, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $12.09
Upside: +65.43%
Teva Pharmaceutical
May 30, 2024
Maintains: Buy
Price Target: $18 → $21
Current: $17.67
Upside: +18.85%
Intra-Cellular Therapies
Apr 17, 2024
Maintains: Buy
Price Target: $82 → $91
Current: $72.65
Upside: +25.26%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $28.50
Upside: +8.77%
Mar 25, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $0.26
Upside: +4,147.10%
Mar 7, 2024
Initiates: Buy
Price Target: $23
Current: $20.22
Upside: +13.75%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $28.83
Upside: +0.59%
Jan 2, 2024
Maintains: Buy
Price Target: $29 → $37
Current: $19.18
Upside: +92.91%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $40.38
Upside: +38.68%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $39.24
Upside: -23.55%
Dec 21, 2023
Maintains: Buy
Price Target: $49 → $51
Current: $28.45
Upside: +79.26%
Nov 17, 2023
Initiates: Neutral
Price Target: $63
Current: $48.35
Upside: +30.30%
Oct 23, 2023
Downgrades: Underperform
Price Target: $9
Current: $11.49
Upside: -21.67%
Aug 10, 2023
Maintains: Buy
Price Target: $204 → $217
Current: $109.04
Upside: +99.01%
Aug 8, 2023
Downgrades: Underperform
Price Target: $4 → $2
Current: $0.39
Upside: +410.20%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $884.48
Upside: -43.47%
May 16, 2023
Maintains: Underperform
Price Target: $6 → $4
Current: $0.29
Upside: +1,293.73%
May 10, 2023
Maintains: Buy
Price Target: $39 → $50
Current: $81.44
Upside: -38.61%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $2.67
Upside: +237.08%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $18.83
Upside: +32.77%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $2.41
Upside: +107.47%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $8.27
Upside: +226.48%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $1.02
Upside: +1,860.78%
Jul 15, 2020
Downgrades: Neutral
Price Target: $17 → $10
Current: $1.37
Upside: +629.93%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $196.96
Upside: -51.77%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $52.90
Upside: +13.42%
Oct 17, 2019
Reinstates: Neutral
Price Target: $37
Current: $28.67
Upside: +29.05%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $114.74
Upside: -21.56%